StreetInsider.com News Articles

Form SCHEDULE 13G/A RadNet, Inc. Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924942.html

Form SCHEDULE 13G/A RadNet, Inc. Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924942.html

RadNet (RDNT) PT Raised to $94 at Truist Securities

Tue, 11 Aug 2026 09:43:13 -0400

Truist Securities analyst David MacDonald raised the price target on RadNet (NASDAQ: RDNT) to $94.00 (from $90.00) while maintaining a Buy rating.

The analyst commented: "Strong 2Q, Momentum Continuing To Build; We remain bullish on RDNT post 2Q results marked by a revenue and adjusted EBITDA beat, strong trends across both segments and raised FY26 guidance reflective of stronger Imaging Center segment trends. Overarching tailwinds remain strong, volumes were ahead across all modalities, advanced procedure growth was better with mix shift accelerating and segment guidance was raised. Digital Health posted another quarter of strong growth, new business trends are strong, recent

RadNet (RDNT) PT Raised to $94 at Truist Securities

Tue, 11 Aug 2026 09:43:13 -0400

Truist Securities analyst David MacDonald raised the price target on RadNet (NASDAQ: RDNT) to $94.00 (from $90.00) while maintaining a Buy rating.

RadNet (RDNT) PT Raised to $96 at B.Riley

Tue, 11 Aug 2026 09:12:30 -0400

B.Riley analyst Yuan Zhi raised the price target on RadNet (NASDAQ: RDNT) to $96.00 (from $83.00) while maintaining a Buy rating.

Form 10-Q RadNet, Inc. For: Jun 30

Mon, 10 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26899067.html

Form 10-Q RadNet, Inc. For: Jun 30

Mon, 10 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26899067.html

Truist Securities Reiterates Buy Rating on RadNet (RDNT)

Mon, 10 Aug 2026 09:12:25 -0400

Truist Securities analyst David MacDonald reiterated a Buy rating and $90.00 price target on RadNet (NASDAQ: RDNT).

The analyst commented: "2Q Ahead On Continued Advanced Procedure Strength, FY Guidance Raised; 2Q Ahead As Volumes Remain Brisk, Margins Come In Better And FY Guidance Raised. RadNet reported strong 2Q results featuring top and bottom-line beats fueled by continued robust advanced procedure growth while FY26 guidance was raised reflecting strong Imaging Center Segment performance. Total revenue of $622.7M came in ahead of our $618.8ME and consensus of $610.9M as the Imaging Center Segment was better than our expectations while Digital Health was roughly

Form 8-K RadNet, Inc. For: Aug 09

Mon, 10 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26893674.html

Form 8-K RadNet, Inc. For: Aug 09

Mon, 10 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26893674.html

RadNet (RDNT) Tops Q2 EPS by 9c; offers guidance

Mon, 10 Aug 2026 02:56:48 -0400

RadNet (NASDAQ: RDNT) reported Q2 EPS of $0.29, $0.09 better than the analyst estimate of $0.20. Revenue for the quarter came in at $622.7 million versus the consensus estimate of $610.01 million.

GUIDANCE:

RadNet sees FY2026 revenue of $2.370-2.420 billion, versus the consensus of $2.493 billion.

For earnings history and earnings-related data on RadNet (RDNT) click here.

RadNet (RDNT) Tops Q2 EPS by 9c; offers guidance

Mon, 10 Aug 2026 02:56:48 -0400

RadNet (NASDAQ: RDNT) reported Q2 EPS of $0.29, $0.09 better than the analyst estimate of $0.20. Revenue for the quarter came in at $622.7 million versus the consensus estimate of $610.01 million.

GUIDANCE:

RadNet sees FY2026 revenue of $2.370-2.420 billion, versus the consensus of $2.493 billion.

For earnings history and earnings-related data on RadNet (RDNT) click here.

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

Sun, 09 Aug 2026 16:00:00 -0400

Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the second quarter of 2026 from $498.2 million in the second quarter of 2025
Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 56.5% to a quarterly record of $32.4 million in the second quarter of 2026 from $20.7 million in the second quarter of 2025; Annual Recurring Revenue⁽⁴⁾ (ARR) increased from $53.5 million at June 30, 2025 to $105.5 million at June 30, 2026 and sequentially increased from $96.9 million at March 31, 2026
Total Company Adjusted EBITDA⁽¹⁾ was a quarterly record of $99.7 million

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

Sun, 09 Aug 2026 16:00:00 -0400

Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the second quarter of 2026 from $498.2 million in the second quarter of 2025
Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 56.5% to a quarterly record of $32.4 million in the second quarter of 2026 from $20.7 million in the second quarter of 2025; Annual Recurring Revenue⁽⁴⁾ (ARR) increased from $53.5 million at June 30, 2025 to $105.5 million at June 30, 2026 and sequentially increased from $96.9 million at March 31, 2026
Total Company Adjusted EBITDA⁽¹⁾ was a quarterly record of $99.7 million

DeepHealth wins FDA clearance for AI breast ultrasound tool

Thu, 30 Jul 2026 16:15:49 -0400

DeepHealth, Inc., a subsidiary of RadNet, Inc. (NASDAQ: RDNT), has received FDA 510(k) clearance for DeepHealth Breast Ultrasound, an AI-powered tool designed to automate lesion detection, characterization, and reporting in breast ultrasound imaging.
The clearance, issued under 510(k) K260303, covers a device manufactured by See-Mode Technologies Pty Ltd, a DeepHealth company, and distributed in the United States by DeepHealth, Inc. The product is now commercially available for sale in the U.S., with customers able to pursue reimbursement under an existing Category III CPT code for quantitative ultrasound tissue characterization, subject to payer policy.
According to a multi-reader multi-case study involving 16 U.S.

DeepHealth wins FDA clearance for AI breast ultrasound tool

Thu, 30 Jul 2026 16:15:49 -0400

DeepHealth, Inc., a subsidiary of RadNet, Inc. (NASDAQ: RDNT), has received FDA 510(k) clearance for DeepHealth Breast Ultrasound, an AI-powered tool designed to automate lesion detection, characterization, and reporting in breast ultrasound imaging.
The clearance, issued under 510(k) K260303, covers a device manufactured by See-Mode Technologies Pty Ltd, a DeepHealth company, and distributed in the United States by DeepHealth, Inc. The product is now commercially available for sale in the U.S., with customers able to pursue reimbursement under an existing Category III CPT code for quantitative ultrasound tissue characterization, subject to payer policy.
According to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound

Thu, 30 Jul 2026 16:15:00 -0400

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S.

RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call

Wed, 22 Jul 2026 06:00:00 -0400

LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2026 financial results on Monday, August 10, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors are invited to listen to RadNet’s conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at